1326 Results
Sort By:
Published on March 20, 2024
A study led by the Science and Technology Facilities Council (STFC) Central Laser Facility (CLF) has demonstrated for the first time that a crucial interface in a protein that drives EGFR resistance to targeted cancer therapies could act as a target for more effective treatments. This research, published in Nature…
Published on November 29, 2023
University of Chicago researchers have identified a nutrient derived from beef, lamb, and dairy products that could enhance cancer therapies. Hao Fan and co-authors report in Nature that the long-chain fatty acid trans-vaccenic acid (TVA) promotes the tumor-infiltrating and cytotoxic functions of CD8+ T cells and “has high translational potential…
Published on November 15, 2023
University of Cambridge spin-out T-Therapeutics announced its series A venture round raised £48 million ($59 million) for the development of novel T-cell receptor (TCR) therapies targeting cancer and inflammatory disorders. The financing was led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures, and Cambridge Innovation Capital. Other participating investors include Sanofi…
Published on June 15, 2022
A new mouse study by researchers at the Perelman School of Medicine at the University of Pennsylvania demonstrates that a stress protein, ATF4, found to play a supportive role in fibroblasts, may be a potential target for future cancer therapies. The findings appear in Nature Cell Biology in a paper titled, “A stromal…
Published on May 5, 2022
A protein called CDC7, which has been known to play an essential role early in the cell division process, can be switched to another protein called CDK1, a finding researchers at Weill Cornell Medicine and the Dana Farber Cancer Institute believe may lead to new cancer therapies. “The entry of…
Published on April 13, 2022
A new bioinformatics platform predicts optimal cancer treatment combinations based on co-occurring tumor alterations, according to work from researchers at University of Texas MD Anderson Cancer Center. In retrospective validation studies, the tool selected combinations that resulted in improved patient outcomes across both pre-clinical and clinical studies. “Our ultimate goal…
Published on January 26, 2022
A study published in Science Advances sheds new insights into the way cells introduce lactate modifications on histones and how these marks are removed again. The researchers hope this new development will improve understanding of the effect of medicine used to treat cancer. Normal cells fuel themselves through a process…
Published on January 12, 2022
Research led by the University of California San Francisco (UCSF) shows that dividing patients according to their individual immune profiles or ‘archetypes’ could result in better responses to cancer immunotherapy than current practice. Immunotherapy has revolutionized the field of oncology, but it is more effective for some patients than others.…
Published on March 2, 2021
Precision medicine company Strata Oncology announced today that Pfizer has joined the Strata Precision Indications for Approved Therapies (Strata PATH) trial, that will take a biomarker-drive approach to identifying new indications for FDA-approved targeted drugs and immunotherapies. To kick off Strata PATH, Pfizer will provide targeted drugs in four study…
Published on August 14, 2020
A discovery of four new cell types in triple negative breast cancer tumors could lead to new and more effective therapies for patients with this cancer, suggest scientists from the Garvan Institute of Medical Research in Australia. The research team used RNA sequencing to analyze gene expression in tumors taken…
Published on July 13, 2020
A large prostate cancer genomics study suggests African-American men, who are disproportionately affected by the cancer, should also benefit from current therapies that target specific genetic mutations causing the disease. However, the researchers—based at Boston University School of Medicine, University of California San Francisco, and Northwestern University—did discover some genetic…
Published on March 30, 2016
Scientists at the University of Colorado Cancer Center published a study (“IMPACT: A Whole-Exome Sequencing Analysis Pipeline for Integrating Molecular Profiles with Actionable Therapeutics in Clinical Samples”) in the Journal of the American Medical Informatics Association (JAMIA) that describes a new tool that interprets the raw data of whole exome tumor sequencing and…
Published on April 17, 2024
Scientists are seeking new ways to develop immunotherapies with different targets especially for patients with these cancers don’t respond to immune checkpoint inhibitors. Now, researchers from Osaka University report that tetracycline antibiotics help the immune system find cancer cells in a way that is different from current immunotherapies. The researchers…
Published on February 14, 2024
Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the National Institutes of Health, and The University of Texas MD Anderson Cancer Center, have shed light on the intricate immune responses within cancerous tumors. By analyzing data from over 1,000 tumors spanning 10 different types of…
Published on November 15, 2023
Scientists have engineered a modified CRISPR technology targeting the epigenome that is capable of modulating T cell behavior. In the process, they discovered a master regulator of the genome that reprograms T cells and enhances their cancer cell-killing ability. Since CRISPR technologies were first developed, much of the interest has…